Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Talbot

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 23, 2003
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancerJ P Braybrooke, M Ranson, C Manegold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatinI E Smith, M E O'Brien, D C Talbot, et al.
British Journal of Cancer|March 10, 2011
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumoursL Medley, A N Morel, D Farrugia, et al.
British Journal of Cancer|January 1, 1997
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancerM I Koukourakis, A Giatromanolaki, K J O'Byrne, et al.
British Journal of Cancer|September 9, 2004
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinomaG Deplanque, S Madhusudan, P H Jones, et al.
The Journal of Clinical Endocrinology and Metabolism|December 17, 1997
A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumorsM P Saunders, A J Salisbury, K J O'Byrne, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2000
Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastineJ P Braybrooke, K A Vallis, S Houlbrook, et al.
Bone Marrow Transplantation|July 1, 1990
Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemiaD C Talbot, R L Powles, J P Sloane, et al.
British Journal of Cancer|November 21, 1998
A phase II study of bryostatin 1 in metastatic malignant melanomaD J Propper, V Macaulay, K J O'Byrne, et al.
Anticancer Research|March 12, 1998
A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazineM P Saunders, A J Salisbury, K J O'Byrne, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|July 23, 2003
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancerJ P Braybrooke, M Ranson, C Manegold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatinI E Smith, M E O'Brien, D C Talbot, et al.
British Journal of Cancer|March 10, 2011
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumoursL Medley, A N Morel, D Farrugia, et al.
British Journal of Cancer|January 1, 1997
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancerM I Koukourakis, A Giatromanolaki, K J O'Byrne, et al.
British Journal of Cancer|September 9, 2004
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinomaG Deplanque, S Madhusudan, P H Jones, et al.
The Journal of Clinical Endocrinology and Metabolism|December 17, 1997
A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumorsM P Saunders, A J Salisbury, K J O'Byrne, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2000
Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastineJ P Braybrooke, K A Vallis, S Houlbrook, et al.
Bone Marrow Transplantation|July 1, 1990
Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemiaD C Talbot, R L Powles, J P Sloane, et al.
British Journal of Cancer|November 21, 1998
A phase II study of bryostatin 1 in metastatic malignant melanomaD J Propper, V Macaulay, K J O'Byrne, et al.
Anticancer Research|March 12, 1998
A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazineM P Saunders, A J Salisbury, K J O'Byrne, et al.
Pageof 7